GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Janux Therapeutics Inc (NAS:JANX) » Definitions » Momentum Rank

Janux Therapeutics (Janux Therapeutics) Momentum Rank : 3 (As of Jun. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Janux Therapeutics Momentum Rank?

Janux Therapeutics has the Momentum Rank of 3.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison of Janux Therapeutics's Momentum Rank

For the Biotechnology subindustry, Janux Therapeutics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Janux Therapeutics's Momentum Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Janux Therapeutics's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Janux Therapeutics's Momentum Rank falls into.



Janux Therapeutics Momentum Rank Related Terms

Thank you for viewing the detailed overview of Janux Therapeutics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Janux Therapeutics (Janux Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
Executives
Tighe Reardon 10 percent owner, officer: Acting Chief Financial Officer C/O SYNTHORX, INC., 11099 NORTH TORREY PINES ROAD, SUITE 190, LA JOLLA CA 92037
Avalon Ventures Xi, L.p. 10 percent owner 1134 KLINE STREET, LA JOLLA CA 92037
Jay Lichter director, 10 percent owner C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Nexus Fund Ii, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Charles M. Winter officer: Chief Technical Officer C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO CA 92130
Winston Kung director C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Byron Robinson officer: Chief Strategy Officer C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson director C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Capital Gp Viii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Orbimed Capital Gp Vii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Alana B. Mcnulty director C/O LUMENA PHARMACEUTICALS, INC., 12531 HIGH BLUFF DRIVE, SUITE 110, SAN DIEGO CA 92130
Ronald W Barrett director C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051